BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25506928)

  • 1. Preparation, pharmacokinetics, biodistribution, antitumor efficacy and safety of Lx2-32c-containing liposome.
    Wang H; Zhang J; Lv G; Ma J; Ma P; Du G; Wang Z; Tian J; Fang W; Fu F
    PLoS One; 2014; 9(12):e114688. PubMed ID: 25506928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative determination of Lx2-32c, a novel taxane derivative, in rat plasma by liquid chromatography-tandem mass spectrometry.
    Hu J; You F; Yang S; Li Y
    J Pharm Biomed Anal; 2014 Jan; 88():483-8. PubMed ID: 24176754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lx2-32c-loaded polymeric micelles with small size for intravenous drug delivery and their inhibitory effect on tumor growth and metastasis in clinically associated 4T1 murine breast cancer.
    Chen LQ; Huang W; Gao ZG; Fang WS; Jin MJ
    Int J Nanomedicine; 2016; 11():5457-5472. PubMed ID: 27799769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo.
    Wang H; Li H; Zuo M; Zhang Y; Liu H; Fang W; Chen X
    Cancer Lett; 2008 Sep; 268(1):89-97. PubMed ID: 18482796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
    Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
    Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lx2-32c inhibits the formation of mammosphere from MDA-MB-231 cells and induces apoptosis involving in down-regulating FoxM1.
    Cai P; Xiao Z; Pan T; Wen X; Cao J; Ouyang B
    Biomed Pharmacother; 2018 Jun; 102():1176-1181. PubMed ID: 29710535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts.
    Ye L; He J; Hu Z; Dong Q; Wang H; Fu F; Tian J
    Food Chem Toxicol; 2013 Feb; 52():200-6. PubMed ID: 23149094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells
    Lv G; Sun D; Zhang J; Xie X; Wu X; Fang W; Tian J; Yan C; Wang H; Fu F
    Acta Pharm Sin B; 2017 Jan; 7(1):52-58. PubMed ID: 28119808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of paclitaxel-containing liposomes in rats.
    Fetterly GJ; Straubinger RM
    AAPS PharmSci; 2003 Nov; 5(4):E32. PubMed ID: 15198520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
    Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
    J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.
    Slingerland M; Guchelaar HJ; Rosing H; Scheulen ME; van Warmerdam LJ; Beijnen JH; Gelderblom H
    Clin Ther; 2013 Dec; 35(12):1946-54. PubMed ID: 24290734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
    Kim TY; Kim DW; Chung JY; Shin SG; Kim SC; Heo DS; Kim NK; Bang YJ
    Clin Cancer Res; 2004 Jun; 10(11):3708-16. PubMed ID: 15173077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety.
    Wang Y; Wu KC; Zhao BX; Zhao X; Wang X; Chen S; Nie SF; Pan WS; Zhang X; Zhang Q
    J Biomed Biotechnol; 2011; 2011():854872. PubMed ID: 21331356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The enhanced longevity and liver targetability of Paclitaxel by hybrid liposomes encapsulating Paclitaxel-conjugated gold nanoparticles.
    Bao QY; Zhang N; Geng DD; Xue JW; Merritt M; Zhang C; Ding Y
    Int J Pharm; 2014 Dec; 477(1-2):408-15. PubMed ID: 25455782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
    Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
    J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
    Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
    Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
    Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
    Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
    Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.